Zydus Cadila gained on Thursday after it received the final approval from the USFDA to market Pottassium Citrate ER tablets 5, 10 and 15 mEq used in the prevention of kidney stones.

The estimated sale in 2014 for potassium Citrate ER tablets is USD 131.7 million, as per IMS.

The group now has 94 approvals and has so far filed 239 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 12.9, or 1.18%, to trade at Rs 1,108. The total volume of shares traded was 2,207 at the BSE (11.05 a.m., Thursday).

The scrip has touched an intra-day high of Rs 1,121.15 and low of Rs 1,096. The total volume of shares traded at the BSE is 2,207.